1. Ariceta G., Besbas N., Johnson S. et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.
2. Barbour T., Johnson S., Cohney S. et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 2012; 27: 2673-2685.
3. Campistol J.M., Arias M., Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013; 33(1): 27-45.
4. Cataland SR, Haifeng M.Wu. Atypical haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopatheis. Eur J Intern Med. 2013;24:486-491.
5. Fakhouri F, Delmas Y, Provot F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. AJKD 2013; http://dx.doi.org/10.1053/ j.ajkd.2013.07.011 6. Kavanagh D., Goodship T.H.J. Atypical hemolytic uremic syndrome. Curr Opin Hematol 2010; 17(5):432-438.
7. Laurence J. Atypical haemolytic uraemic syndrome (aHUS): treating the patient. Clin Adv Hematol Oncol 2013; 11(10), Sup-pl.15:3-15
8. Legendre CM, Licht C, Greenbaum LA et al. Terminal complement inhibitor eculizumab in atypical haemolytic uraemic syndrome. N Engl J Med. 2013; 368(23):2169-2181.
9. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical haemolytic uraemic syndrome. Semin Thromb Hemost 2010:36:673-681
10. Лора Ш., Фремю-Бачи В. Атипичный гемолитико- уремический синдром// Нефрология.- 2012; т. 16, №2, с.16-48.
11. Meri S. Complement activation in deseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013; http://dx.doi. org/10.1016/ j.ejim.2013.05.009
12. Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is this, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012:617-25.
13. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.
14. Noris M., Caprioli J, Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844-1859
15. Scully M., Hunt B.J., Bemjamin S. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopatheis. BJH 2012; 158 (3): 323—335.
16. Scully M., Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. BJH 2014; doi:10.1111/bjh.12718
17. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH.2009;148:37-47
18. Tsai HM. Thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. An Update. Hematol Oncol Clin N Am 2013;27:565-584
19. Zuber J., Fakhouri F., Roumenina L.T. et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomeru-lopahties. Nat. Rev. Nephrol. 2012; 8, 643-657.
20. Zuber J., Le Quintrec M, Sberro-Soussan R. Et al. New Insight into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23-35